Edwards Lifesciences (EW) Cash & Current Investments (2016 - 2025)
Edwards Lifesciences (EW) has 17 years of Cash & Current Investments data on record, last reported at $4.2 billion in Q4 2025.
- For Q4 2025, Cash & Current Investments rose 6.3% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $4.2 billion, up 6.3%, while the annual FY2025 figure was $4.2 billion, 6.3% up from the prior year.
- Cash & Current Investments reached $4.2 billion in Q4 2025 per EW's latest filing, up from $3.8 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $4.4 billion in Q3 2024 and bottomed at $1.2 billion in Q4 2022.
- Average Cash & Current Investments over 5 years is $2.3 billion, with a median of $1.7 billion recorded in 2022.
- Peak YoY movement for Cash & Current Investments: decreased 17.66% in 2022, then surged 143.5% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $1.5 billion in 2021, then decreased by 17.66% to $1.2 billion in 2022, then surged by 35.19% to $1.6 billion in 2023, then soared by 143.5% to $4.0 billion in 2024, then rose by 6.3% to $4.2 billion in 2025.
- Per Business Quant database, its latest 3 readings for Cash & Current Investments were $4.2 billion in Q4 2025, $3.8 billion in Q3 2025, and $4.1 billion in Q2 2025.